Top stories

Argentina

Lithium Argentina AG Announces $180M Investment and Joint Venture

Lithium Argentina AG finalized a joint venture for its Pozuelos-Pastos Grandes projects and secured a strategic investment from Ganfeng Lithium.

Buenos Aires Puerto Madero 30
Sydney CBD Skyline at dusk
Australia

Axel REE's Bigger Woolrich Resource Still Has to Show ISR Can Work

Axel REE (ASX: AXL) has more than doubled its Woolrich rare earth resource, lifting its Caladão project in Brazil by 24 percent. The harder test is whether in situ recovery works under field conditions, and no technical study has been completed yet.

News by Continent

The latest report from each continent we cover.

Oceania

Nexsen's GBS Diagnostic Bet: A Joint Venture to Bridge the APAC Gap

Nexsen Limited (ASX: NXN) is forming a 50:50 joint venture with FlashDx Shenzhen to commercialise an enhanced molecular Group B Streptococcus diagnostic, targeting FDA and EU regulatory clearances alongside immediate Asia-Pacific market entry.

Australia

News by Sector

The latest report from each sector we track.

Healthcare

Veracyte's Decipher Test Faces the Real-World Test at ASTRO

Veracyte (Nasdaq: VCYT) has eight studies on its Decipher prostate cancer test at ASTRO 2026, but no findings have been disclosed yet. GSN asks whether the data will show the genomic classifier can help guide treatment decisions.

United States

Stocks to Watch

Little-known stocks with breakthrough news, surfaced weekly.

Latest News

Dallas Skyline in the evening
United States

Veracyte's Decipher Test Faces the Real-World Test at ASTRO

Veracyte (Nasdaq: VCYT) has eight studies on its Decipher prostate cancer test at ASTRO 2026, but no findings have been disclosed yet. GSN asks whether the data will show the genomic classifier can help guide treatment decisions.

Melbourne (AU), Melbourne City Centre 2019 1493 7
Australia

Nexsen's GBS Diagnostic Bet: A Joint Venture to Bridge the APAC Gap

Nexsen Limited (ASX: NXN) is forming a 50:50 joint venture with FlashDx Shenzhen to commercialise an enhanced molecular Group B Streptococcus diagnostic, targeting FDA and EU regulatory clearances alongside immediate Asia-Pacific market entry.

Sydney CBD Skyline at dusk
Australia

Axel REE's Bigger Woolrich Resource Still Has to Show ISR Can Work

Axel REE (ASX: AXL) has more than doubled its Woolrich rare earth resource, lifting its Caladão project in Brazil by 24 percent. The harder test is whether in situ recovery works under field conditions, and no technical study has been completed yet.

Market Explainers